Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia ...
A new clinical trial is enrolling up to 60 children and young people with solid tumors across the United States and United ...
Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, a research team led by Christian ...
CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine ...
Allogene Therapeutics’ gamble on a never-before-seen trial strategy seems to be paying off, with the biotech’s off-the-shelf cell therapy eradicating residual lymphoma in over half of evaluated pat | ...
CAR-T cell therapy puts woman's three autoimmune diseases into remission after single infusion when nine previous treatments ...
U.S. FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia / T Cell Lymphoblastic Lymphoma -- Breakthrough ...
Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These ...
Axi-cel demonstrated superior progression-free survival compared to tisa-cel, despite a higher toxicity profile, including increased neurotoxicity and cytokine release syndrome. The CAR-HEMATOTOX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results